试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-09
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
编号:NCT03615924登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Ticagrelor、Placebo
登记的停止原因(原文):Recommendation from an independent data monitoring committee (DMC) and accepted by AstraZeneca.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-09
ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic
编号:NCT04329195登记状态:提前终止企业 / 申办者:Assistance Publique - Hôpitaux de Paris
药物 / 成分:1: discontinuation of RAS blocker therapy、2: continuation of RAS blocker therapy
登记的停止原因(原文):insufficient recrutment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
Pilot Study of Safety and Efficacy of Spheramine
编号:NCT00761436登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:Spheramine (BAY86-5280)
登记的停止原因(原文):Study was completed, only life long extended follow-up phase was discontinued after 12 years
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)
编号:NCT01573338登记状态:提前终止企业 / 申办者:Bayer
药物 / 成分:Roniciclib (BAY1000394)、Etoposide、Cisplatin、Carboplatin
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
Comparison of Nebulizers in ED in Pediatric Asthma Patients
编号:NCT01951378登记状态:提前终止企业 / 申办者:Seton Healthcare Family
药物 / 成分:Hudson RCI® nebulizer、NebuTech® HDN® nebulizer、Albuterol
登记的停止原因(原文):No data are available for this study as the PI has left the institution.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
编号:NCT02036502登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Pembrolizumab、Lenalidomide、Dexamethasone、Carfilzomib
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
编号:NCT02186821登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:Ceritinib
登记的停止原因(原文):Study was terminated due to low enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
编号:NCT02336048登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Chlorambucil、Obinutuzumab、Placebo、Standard Premedication
登记的停止原因(原文):This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
CleanUP IPF for the Pulmonary Trials Cooperative
编号:NCT02759120登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Antimicrobial therapy: Co-trimoxazole or Doxycycline、No Intervention: Standard of Care
登记的停止原因(原文):Terminated for futility after review of first planned interim analysis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2021-04-08
Prunes for Gastrointestinal Function After Gynecologic Surgery
编号:NCT03523715登记状态:提前终止企业 / 申办者:University of Southern California
药物 / 成分:Prunes、Docusate Sodium
登记的停止原因(原文):Difficulty in recruiting participants
查看官方原始记录 ↗